India’s Life Sciences and Healthcare (LSHC) GCC sector is set for rapid expansion, aiming for a $100 billion valuation by 2030, with 2,500 centers and 4.5 million professionals by 2025. This growth is driven by India’s deep tech talent, cost advantages, and a thriving innovation ecosystem. Global pharma and healthcare leaders increasingly rely on Indian GCCs for drug discovery, clinical trials, commercial operations, and advanced data analytics.
Key factors fueling this surge include GCC-startup collaborations, Tier-II city expansions, and the adoption of AI, IoT, and blockchain. Healthark’s LSHC GCC Outlook 2025 explores India’s strategic advantages, emphasizing next-gen talent and cutting-edge frameworks. This whitepaper highlights emerging trends and India’s growing influence in reshaping the global LSHC landscape, reinforcing its position as a leader in operational efficiency and healthcare innovation for the next decade.
